Vomiting News and Research

RSS

Vomiting is the process the body uses to eject some or all of the contents of the stomach through the mouth.

Iron deficiency during pregnancy may impact child's brain development

A mother's iron deficiency early in pregnancy may have a profound and long-lasting effect on the brain development of the child, even if the lack of iron is not enough to cause severe anemia, according to a University of Rochester Medical Center study published in the scientific journal PLoS One.

23 Mar 2011

Milk allergy successfully treated with Xolair

A latest study suggests that children with severe milk allergies may be able to rapidly overcome their sensitivities with the help of a biologic drug that helps to quiet an overly aggressive immune response. This is a small study still waiting to be proved in larger populations say researchers.

22 Mar 2011

CSL Behring presents Hizentra study data against PI at AAAAI meeting

Data presented by CSL Behring today suggest that treatment with higher dose Hizentra correlates with reduced risk of infection and missed school or work among patients with primary immunodeficiencies.

22 Mar 2011

BDSI's BEMA drug delivery technology receives Canada patent

BioDelivery Sciences International, Inc. announced the issuance of a patent extending the exclusivity of the BioErodible MucoAdhesive drug delivery technology in Canada from 2017 to 2027. The patent was been reviewed by the Office of Patented Medicines for listing in the Canadian Patent Register and was found eligible for listing.

22 Mar 2011

BioMarin announces preliminary results from ADAPT in patients suffering from PKU

BioMarin Pharmaceutical Inc. announced today preliminary results from ADAPT (A Diversified Approach for PKU Treatment) in an abstract (Abstract #91, Mental Health Screening in Phenylketoniuria Clinic) presented by Barbara Burton, MD at the 2011 annual American College of Medical Genetics conference in Vancouver, Canada.

19 Mar 2011

Experts advise against taking unnecessary potassium iodide

There is a mad rush to the stores to pick up potassium iodide supplements to guard against radiation exposure wafting over to the U.S. from Japan, an unlikely event according to experts. This is despite health officials’ warnings that these supplements are pointless and could cause adverse side effects.

16 Mar 2011

Experimental vaccine against human norovirus generates strong, safe immune response in mice

Scientists have shown that an experimental vaccine against the human norovirus - the bug behind about 90 percent of highly contagious nonbacterial illnesses that cause diarrhea and vomiting - can generate a strong immune response in mice without appearing to cause the animals any harm.

16 Mar 2011

FDA clears Intralytix phage-based EcoShield food safety product

Intralytix, Inc. announced today that it has received regulatory clearance from the Food and Drug Administration for its phage-based EcoShield food safety product, effective against E. coli O157:H7.

16 Mar 2011

Radiation exposure explained

Amidst threat of major nuclear accident in Japan, people are in a state of panic worldwide said Jerrold Bushberg, a medical physicist at UC Davis. Bushberg said Americans do not have a good knowledge of the science of radiation and tend to over-exaggerate the risks.

14 Mar 2011

Transcept initiates enrollment in TO-2061 Phase 2 study for treatment resistant obsessive compulsive disorder

Transcept Pharmaceuticals, Inc. today announced the first patient has been enrolled in a Phase 2 clinical study to evaluate TO-2061 as an adjunctive treatment for obsessive compulsive disorder (OCD) in patients who have responded inadequately to currently approved treatments. OCD affects 1 to 2 percent of the United States adult population and can significantly impair the lives of patients and their families.

14 Mar 2011

Parents need to talk to kids about eating disorders as early as possible

A government study has found that more than half a million teens have had an eating disorder, most commonly in the form of binge eating disorder and bulimia, and that most of the time these go untreated.

11 Mar 2011

BDSI prices $15 million private placement

BioDelivery Sciences International, Inc. announces that it has received definitive commitments from institutional investors for a private placement financing yielding gross proceeds of $15 million to BDSI. The financing is expected to close today.

11 Mar 2011

NIH awards Avaxia Phase I SBIR grant to develop novel antibody therapeutic for celiac disease

Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody therapeutics for the treatment of gastrointestinal diseases, announced today that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (NIH), to support the development of a novel antibody therapeutic for celiac disease.

11 Mar 2011

Positive results from exenatide phase 2 study in patients with type 2 diabetes

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced positive results from a phase 2 study evaluating the effects of a once-monthly injectable suspension formulation of exenatide on glycemic control in patients with type 2 diabetes.

10 Mar 2011

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced that several new data analyses from Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be presented at The International Liver CongressTM / 46th European Association for the Study of the Liver annual meeting.

9 Mar 2011

BioAlliance Pharma awarded €2 million in funding to study Lauriad mucoadhesive technology

BioAlliance Pharma SA, a company dedicated to the supportive care and treatment of cancer patients, today announced the award of €2 million in funding over 30 months from the « Fond Unique Interministériel » (a French program supporting collaborative research projects) including an amount of €743,000 specifically allocated to BioAlliance Pharma.

5 Mar 2011

Giant Food removes McCormick's Golden Dipt Tempura Seafood Batter Mix from stores

Following notification from its supplier, McCormick & Company, Giant Food has removed from stores McCormick's Golden Dipt Tempura Seafood Batter Mix. The product may contain milk, an undeclared allergen.

5 Mar 2011

Vertex announces positive interim results from telaprevir Phase 2 study in patients with HCV, HIV

Vertex Pharmaceuticals Incorporated announced today interim results from an ongoing, two-part, Phase 2 study evaluating telaprevir in combination with pegylated-interferon and ribavirin compared to pegylated-interferon and ribavirin alone in people who are infected with both genotype 1 hepatitis C virus and human immunodeficiency virus, also known as HCV-HIV co-infection.

3 Mar 2011

Regeneron's ARCALYST meets primary, secondary endpoints in second Phase 3 gout flare study

Regeneron Pharmaceuticals, Inc. announced that in a second Phase 3 study (PRE-SURGE 2) in gout patients initiating allopurinol therapy, ARCALYST (rilonacept) met the primary and all secondary study endpoints. The primary endpoint was the number of gout flares per patient over the 16-week treatment period.

28 Feb 2011

Genentech granted FDA hearing on Avastin for metastatic breast cancer

Genentech, a member of the Roche Group, today announced the U.S. Food and Drug Administration (FDA) has granted a hearing to allow the company the opportunity to present its views on why Avastin® (bevacizumab) should remain FDA-approved for metastatic breast cancer (mBC). The FDA has scheduled the hearing for June 28 to 29, 2011.

25 Feb 2011

Vomiting News and Research

Further Reading

Iron deficiency during pregnancy may impact child's brain development

Milk allergy successfully treated with Xolair

CSL Behring presents Hizentra study data against PI at AAAAI meeting

BDSI's BEMA drug delivery technology receives Canada patent

BioMarin announces preliminary results from ADAPT in patients suffering from PKU

Experts advise against taking unnecessary potassium iodide

Experimental vaccine against human norovirus generates strong, safe immune response in mice

FDA clears Intralytix phage-based EcoShield food safety product

Radiation exposure explained

Transcept initiates enrollment in TO-2061 Phase 2 study for treatment resistant obsessive compulsive disorder

Parents need to talk to kids about eating disorders as early as possible

BDSI prices $15 million private placement

NIH awards Avaxia Phase I SBIR grant to develop novel antibody therapeutic for celiac disease

Positive results from exenatide phase 2 study in patients with type 2 diabetes

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

BioAlliance Pharma awarded €2 million in funding to study Lauriad mucoadhesive technology

Giant Food removes McCormick's Golden Dipt Tempura Seafood Batter Mix from stores

Vertex announces positive interim results from telaprevir Phase 2 study in patients with HCV, HIV

Regeneron's ARCALYST meets primary, secondary endpoints in second Phase 3 gout flare study

Genentech granted FDA hearing on Avastin for metastatic breast cancer

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News